ARTICLE | Company News
Therapeutic Antibodies, Searle deal
January 25, 1999 8:00 AM UTC
The companies terminated their 1998 agreement to develop an antibody that would reverse the effects of Searle's xemilofiban and orbofiban oral GPIIb/IIIa receptor antagonists. The termination follows...